Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 10/20 | 0.49 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.46 |
| ▸ | DAO | P14920 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | PTPN7 | P35236 | 3/20 | 0.40 |
| ▸ | DUSP3 | P51452 | 3/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30841977 | 1.00 | KIF11 (0.49) | KIF11P2RX7DAOPPARGPPARD | |
| SCHEMBL297375 | 0.85 | PTPN7 (0.52) | P2RX7PTPN7DUSP3HTR2ASLC6A4 | |
| SCHEMBL18199697 | 0.85 | EPHX2 (0.38) | KIF11P2RX7PTPN7DUSP3HTR2A | |
| SCHEMBL31502480 | 0.85 | KIF11 (0.51) | KIF11P2RX7DAOPPARGPPARD | |
| SCHEMBL23775244 | 0.82 | EPHX2 (0.37) | KIF11P2RX7PPARGPTPN7DUSP3 | |
| SCHEMBL13452393 | 0.82 | KIF11 (0.46) | KIF11P2RX7DAOPPARGPPARD | |
| SCHEMBL13590952 | 0.82 | TAAR1 (0.52) | KIF11DAO | |
| SCHEMBL13452630 | 0.80 | MRGPRX4 (0.45) | P2RX7DAOHTR2ASLC6A4KCNH2 | |
| SCHEMBL12706035 | 0.79 | KIF11 (0.53) | KIF11P2RX7DAOKDM1A | |
| SCHEMBL5208895 | 0.78 | P2RX7 (0.56) | KIF11P2RX7PPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122028918-A | TRIM7 inhibitors and uses thereof | 沙塔克实验室有限公司 | 2026-05-12 | — | — | CN | disclosed |
| EP-4251624-B1 | TRICYCLIC CARBOXAMIDE DERIVATIVES AS PRMT5 INHIBITORS | AMGEN INC (US) | 2025-10-29 | — | — | EP | disclosed |
| WO-2025042798-A1 | TRIM7 INHIBITORS AND USES THEREOF | SHATTUCK LABS, INC. (US) | 2025-02-27 | — | — | WO | disclosed |
| US-20240101570-A1 | TRICYCLIC CARBOXAMIDE DERIVATIVES AS PRMT5 INHIBITORS | AMGEN INC. | 2024-03-28 | — | — | US | disclosed |
| WO-2022115377-A1 | TRICYCLIC CARBOXAMIDE DERIVATIVES AS PRMT5 INHIBITORS | AMGEN INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| EP-3544961-B1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | UNIV VANDERBILT (US) | 2021-08-18 | — | — | EP | disclosed |
| EP-2200982-B1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-03-14 | — | — | EP | disclosed |
| EP-2200982-B1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-03-14 | — | — | EP | disclosed |
| US-20110021565-A1 | PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | KNUST HENNER | 2011-01-27 | — | — | US | disclosed |
| US-20110021565-A1 | PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | KNUST HENNER | 2011-01-27 | — | — | US | disclosed |
| US-7592345-B2 | Piperazine and [1,4]diazepan derivatives as NK antagonists | HOFFMANN-LA ROCHE INC. (US) | 2009-09-22 | — | — | US | disclosed |
| WO-2009033995-A1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-03-19 | — | — | WO | disclosed |
| US-20090076081-A1 | PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2009-03-19 | — | — | US | disclosed |
| US-20090076081-A1 | PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2009-03-19 | — | — | US | disclosed |
| WO-2009033995-A1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-03-19 | — | — | WO | disclosed |
| US-20090076081-A1 | PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2009-03-19 | — | — | US | disclosed |
| EP-1995241-A1 | Inhibitors of ion channels | ICAgen, Incorporated (US) | 2008-11-26 | — | — | EP | disclosed |
| WO-2008118758-A1 | INHIBITORS OF ION CHANNELS | ICAGEN, INC. (GB) | 2008-10-02 | — | — | WO | disclosed |
| US-7351742-B2 | Sulfonamide derivatives for the treatment of diseases | PFIZER INC. (US) | 2008-04-01 | — | — | US | disclosed |
| WO-2008011116-A2 | AZA-PEPTIDE PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101570-A1 | TRICYCLIC CARBOXAMIDE DERIVATIVES AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | KIF11 4029/4885P2RX7 4544/4885DAO 2432/4885 |
| US-20090076081-A1 | PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | DRD2, DRD3, OPRL1 | KIF11 417/4885P2RX7 146/4885DAO 3721/4885 |
| US-20110021565-A1 | PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | DRD2, DRD3, OPRL1 | KIF11 417/4885P2RX7 146/4885DAO 3721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.